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Abstract
Background Hiatal repair failure is the nemesis of lapa-
roscopic paraesophageal hernia repair as well as the major
cause of failure of primary fundoplication and reoperation
on the hiatus. Biologic prosthetics offer the promise of
reinforcing the repair without risks associated with per-
manent prosthetics.
Design Retrospective evaluation of safety and relative
efficacy of laparoscopic hiatal hernia repair using an allo-
graft (acellular dermal matrix) onlay. Patients with symp-
tomatic failures underwent endoscopic or radiographic
assessment of hiatal status.
Results Greater than 6-month follow-up was available for
252 of 450 consecutive patients undergoing laparoscopic
allograft-reinforced hiatal hernia repair between January
2007 and March 2011. No erosions, strictures, or persisting
dysphagia were encountered. Adhesions were minimal in
cases where reoperation was required. Failure of the hiatal
repair at median 18 months (6–51 months) was signifi-
cantly (p \ 0.005) different between groups: group A
(primary fundoplication with axial hernia B 2 cm), 3.7 %;
group B (primary fundoplication with axial hernia
2–5 cm), 7.1 %; group G (giant/paraesophageal), 8.8 %;
group R (reoperative), 23.4 %. Additionally, mean time to
failure was significantly shorter in group R (247 days)
compared with the other groups (462–489 days).
Conclusions Use of allograft reinforcement to the hiatus
is safe at 18 months median follow-up. Reoperations had a
significantly higher failure rate and shorter time to failure
than the other groups despite allograft, suggesting that
primary repairs require utmost attention and that additional
techniques may be needed in reoperations. Patients with
hiatal hernias[2 cm axially had a recurrence rate equal to
that of patients undergoing paraesophageal hiatal hernia
repair, and should be treated similarly.
Keywords Allograft  Acellular dermal matrix  Biologic
mesh  Biomesh  Biologic prosthetic  Hiatoplasty  Hiatal
hernia repair  Laparoscopic paraesophageal hernia repair 
Routine mesh laparoscopic fundoplication
Recurrence of hiatal hernia is the nemesis of treatment of
giant or paraesophageal hernias [1, 2]. It is also the major
reason for failure after laparoscopic primary fundoplication
[3–6] and, though not as well documented, the most
common reason for failure after reoperation on the
esophageal hiatus [7, 8]. Although this issue has been
recognized for some time, debate still continues as to
whether prosthetic reinforcement of the hiatus has enough
benefit to offset potential risks of erosion or adhesion
[9–12].
Following reports of short-term benefit to collagenous
prosthetic reinforcement of the hiatus [13], in 2007 we
began using an allograft dermal matrix (Allomax; Davol,
Inc., Warwick, RI) as an onlay after primary suture repair
of giant or paraesophageal hernias. The experience was
then extended to using this prosthetic in recurrent hiatal
hernias, in line with surgical principles learned from
repairing recurrent ventral and groin hernias. Extension of
this concept brought us to consider the use of an allograft
onlay after repair of all hiatal hernias during primary fun-
doplication. This study is a retrospective analysis of our
experience in using a single type of allograft dermal matrix
in all patients having laparoscopic hiatal hernioplasty
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during primary fundoplication, repair of giant/paraesoph-
ageal hernias, or revisional surgery.
Materials and methods
Study population
Beginning in January 2007, all patients undergoing lapa-
roscopic hiatal hernia repair (whether as part of a fundo-
plication for reflux control, or repair of a giant hiatal
hernia, or reoperation for failed prior surgery) were rein-
forced with a dermal allograft onlay when primary hiatal
closure could be performed. This patient population had
been followed clinically and represents the cohort for this
retrospective study.
Study design and endpoints
This retrospective study was approved by the HealthOne
institutional review board (IRB) and is registered at irbnet.
org (IRBNet ID: 231822-3). As a retrospective study of a
clinical database, informed consent was not required.
Treatment
The treatment employed for the study was reinforcement of
primary closure of the hiatus using an allograft dermal
matrix (Allomax; Davol, Inc.). This allograft is terminally
sterilized human dermal collagen of 0.8 mm to 1.8 mm
thickness. Using a proprietary process, all noncollagenous
cellular components are removed but constituent elastin
fibers remain. The allograft is not cross-linked.
Patient stratification
Patients were stratified into four groups. Group A consisted
of patients presenting with an axial hiatal hernia of B2 cm.
Group B patients had a presenting axial hiatal hernia
[2 cm but less than 6 cm, without significant paraesoph-
ageal component. Group G (giant) was formed of patients
with a giant or paraesophageal hiatal hernia, regardless of
the axial height of the hernia. Group R (redo) was formed
of patients undergoing reoperation for a failed prior pro-
cedure on the hiatus or gastroesophageal (GE) junction,
regardless of the size of the hernia.
Safety
Adverse events were defined as dysphagia requiring dila-
tion in the first 3 postoperative months, dysphagia requiring
reoperation, mesh erosion or infection. In addition, density
of adhesions at reoperation was recorded.
Endpoints
Subjective outcomes were assessed by patient self-reported
assessment of the success or failure of the procedure.
Clinical failure was defined as any recurrence or develop-
ment of troublesome typical GE reflux disease (GERD)
symptoms more than 2–3 times per week.
Patients who reported clinical failure were asked to
undergo objective evaluation to determine if recurrent
reflux or recurrent hiatal hernia was present. Objective
outcomes were assessed using esophagogastroduodeno-
scopy (EGD) and/or barium swallow. Failure of the hiatal
repair was defined as [2 cm axial component to hiatal
hernia, or any degree of paraesophageal herniation or
transthoracic wrap migration, by either study.
Preoperative assessment
All patients undergoing surgery had objective evidence of
GERD, objective evidence of a giant hiatal hernia, or
postfundoplication symptoms severe enough to warrant
reoperation (e.g., dysphagia). Patients having surgery for
GERD had medically refractory GERD, desired an alter-
native to medical therapy, or had laryngopharyngeal
symptoms thought likely due to GERD. The great majority
of GERD patients had preoperative ambulatory reflux
testing, endoscopy, and esophageal manometry. Patients
having surgery for a giant or paraesophageal hiatal hernia
had preoperative endoscopy and, when indicated, barium
swallow or esophageal manometry. Patients undergoing
reoperation had preoperative endoscopy, ambulatory reflux
testing, and manometry whenever possible. Solid gastric
emptying studies were obtained selectively. Informed
consent included the use of a prosthetic reinforcement of
the hiatal closure.
Technique
During laparoscopic surgery on the hiatus, following dis-
section of the phrenoesophageal membrane and excision of
the hernia sac (if present), mediastinal mobilization of the
esophagus was performed until adequate (2–3 cm) intra-
abdominal esophagus was obtained. Evaluation of the
location of the angle of His both laparoscopically and by
the gastroesophageal junction (or end of the tubular
esophagus) was used. If adequate length could not be
obtained, a Collis gastroplasty was performed with a single
endoscopic linear staple line, the stapler being introduced
through the left chest.
Once adequate esophagus or neoesophagus was obtained
to permit a tensionless fundoplication, the diaphragm
hiatus was closed using nonabsorbable polyester suture
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(0-Ethibond; Ethicon, Inc.). Sutures were placed primarily
posteriorly; however, anterior and/or left-sided figure-
of-eight sutures were placed when needed to close the hiatus.
Hiatal orifice following closure was between 2.5 and 3 cm
diameter without a bougie, which is equivalent to precise
closure around a 60-Fr bougie.
Once primary closure was accomplished, an allograft
dermal matrix (Allomax; Davol Inc.) was placed as an
onlay over the repair. Initially, the allograft was placed
just over the posterior closure as a heart-shaped patch;
gradually, the shape of the patch evolved to a ‘‘U’’- and
then to a ‘‘C’’-shaped patch. The patch was secured in
place with three or four absorbable monofilament 3-0
sutures at the edges of the hiatus and to the dorsal aspect
of the crural closure; further sutures were placed at the far
edges of the patch to distribute tension when judged
clinically necessary (Fig. 1). Care was taken that the
patch lay smoothly against the peritoneal (defatted) sur-
face of the diaphragm. Initially the patch was placed with
the dermal side against the diaphragm; beginning in 2009,
as a result of anecdotal feedback from plastic surgeons,
the patch was placed with the epidermal side toward the
diaphragm. [If primary closure could not be achieved, a
permanent polytetrafluoroethylene (PTFE) patch was used
to complete the hiatal closure; these five patients are not
part of this analysis.]
A fundoplication (Nissen or Toupet) was performed in
all instances after the hiatal closure, even for paraesopha-
geal hernias without reflux symptoms. The fundoplication
was not secured to the crura; in the Toupet, two suspensory
sutures were placed to the diaphragm 1 cm away from the
hiatus at 11 and 1 o’clock (considering the hiatus as a clock
face, viewed from below).
Antibiotics were not routinely administered.
Postoperative care
Postoperative care involved commonly accepted practices
of antiemetic medication and gradual reintroduction of
thicker-consistency foods. Patients were instructed to avoid
heavy lifting or vigorous exercise for 4 weeks after
surgery.
Follow-up assessments
Patients were contacted as part of our routine clinical
practice in patients undergoing laparoscopic fundoplication
or hiatal hernia repair. Intervals of follow-up varied as
clinical practice permitted. Patients were asked to gauge
the success of the surgery. Patients who met criteria for
clinical failure were asked to undergo objective evaluation
to determine the cause of failure. Additionally, any patient
who had troublesome dysphagia or chest pain was asked to
undergo objective evaluation.
Data analysis
Data were entered into an electronic database system
(Microsoft Access) and monitored for accuracy against the
source documents. Aggregate data with patient demo-
graphics, baseline characteristics, efficacy, safety, and
patient satisfaction results were summarized by descriptive
statistics. Mean, standard deviation (SD), and standard error
of mean (SEM) were generally reported for continuous
variables. Median and range were reported for data with
skewed distribution. p-Values for changes at follow-up
compared with baseline were calculated using the Mann–
Whitney U and paired t test. Fisher’s exact test was used to
compare frequencies. Multiple groups were compared using
analysis of variance (ANOVA) or Kruskal–Wallis test.
Values with p \ 0.05 were considered significant. All
analyses were performed using XL Stat software.
Results
Patient characteristics at baseline
Between 1 January 2007 and 31 May 2011, 400 patients
underwent laparoscopic hiatal hernia repair with rein-
forcement using the allograft. Attempts by phone, email,
and letter resulted in 252 patients available for follow-up.
Baseline characteristics of the entire study population as
well as stratification of the four groups are presented in
Table 1.
Of the 252 patients, 244 were on proton pump inhibitor
(PPI) therapy at presentation, only 10 % reported C90 %Fig. 1 Operative photograph of allograft onlay
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response of their primary symptom to PPI therapy, and
median response to PPI therapy was 25 %.
Category of presenting primary symptoms per group is
presented in Fig. 2.
All patients had objective evidence of GERD or a
concerning giant/paraesophageal hiatal hernia prior to
surgery. Objective evidence included abnormal ambulatory
reflux monitoring, erosive esophagitis [LA class A,
columnar-lined epithelium (CLE) with or without special-
ized intestinal metaplasia (SIM), or a large fixed or para-
esophageal hiatal hernia with chest pain, dysphagia, or
evidence of organoaxial volvulus.
Group A [axial hiatal hernia (HH) B 2 cm] consisted of
81 patients, and group B consisted of 56 patients (axial HH
[2 to \6 cm), undergoing primary fundoplication for
GERD. Group G consisted of 68 patients with axial hiatal
hernias of at least 6 cm, or paraesophageal hernias,
undergoing primary surgery. All of these patients under-
went a fundoplication after the hernia repair. Group R
consisted of 47 patient undergoing revisional surgery for a
failed prior fundoplication or prior hiatal hernia repair (35
with one prior surgery, 7 with two prior surgeries, and 3
with three prior surgeries). The precise reasons for the
primary surgery in these patients, e.g., primary GERD or
paraesophageal hernia, were frequently not available even
after review of the original operative reports, but for the
most part appeared to be primary GERD. Operative details
are reviewed in Table 2.
As would be expected from the initial patient grouping,
hiatal characteristics varied between groups. The giant
hiatal hernia group required more extensive mediastinal
mobilization, and 27 % received Collis gastroplasty. Both
giant and redo groups had more anterior and left crural
closure sutures placed than the primary groups (A and B).
Procedure and safety outcomes
Three patients had postoperative perigastric infections, all
within the first 20 days of surgery; all were in the reoper-
ation group. In these three patients the infection resolved
without removal of the allograft.
Fourteen patients (5.6 %) required more than one dila-
tion in the first 90 days after surgery. These patients typi-
cally evidenced resistance to passage of a Maloney dilator
at initial dilation; serial radial and bougie dilations to
18 mm (generally three procedures) resulted in loss of
resistance and relief of dysphagia in all five. Although a
greater percentage of group A required dilation (8.6 %
versus 1.8–4.3 %), this did not reach statistical significance
(p = 0.2, Chi square). There were three instances of hiatal
stenosis that underwent laparoscopic release after failed
dilations (one, three, and three). The hiatus was simply
incised on the right anterior aspect sufficiently to admit a
56-Fr Maloney dilator without resistance. These patients
were early in our series, and all experienced immediate
relief of the dysphagia and ability to eat a solid diet within
1 week of the release.
No instances of allograft erosion were observed in this
series, nor have any been observed in more than 450
patients operated on to date.
Patients who came for reoperation with prior allograft
placement did not evidence significant or difficult adhe-
sions. In fact, the solitary permanent braided polymer
suture that was used to secure the mesh generated
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significantly denser adhesions than the allograft. An
empirical observation is also that tissue sealants/glue gen-
erate much greater difficulty during reoperation than does
the allograft.
Outcomes
All patients had follow-up[180 days with the exception of
five early failures going to reoperation; mean follow-up
was 17.7 months (6–51 months). No significant difference
in follow-up duration existed between the four groups.
Failure of hiatal repair was defined as development of
esophageal symptoms with objective evidence of trans-
thoracic migration of the wrap or the stomach. Overall, 24
patients (9.5 %) evidenced symptomatic failure due to
recurrent hiatal hernia. (All patients with subjective
recurrence agreed to objective testing to determine their
hiatal anatomy.) Group A (B2 cm) developed symptomatic
hiatal failure in 3.7 % of cases, whereas the 2–5-cm axial
hernias (group B) and the giant hiatal hernia groups failed
at a similar rate (7.1 % and 8.8 %). The reoperative group
(R) failed at a significantly greater rate of 23.4 % at
18 months (p \ 0.003, Chi square) (Fig. 3). No symp-
tomatic failures possessed preoperative body mass index
(BMI)[40 kg/m2. (Twelve patients possessed preoperative
BMI [40 kg/m2; five were [45 kg/m2.) Four failures
occurred in 41 patients with preoperative BMI [35 kg/m2
(10 %), no different from the overall group. Numbers of
patients with various BMI in the subgroups were too small
to draw any conclusions.
Time to failure was also analyzed, and again the reop-
erative group failed significantly earlier (mean 247 days)
compared with the three other groups (462–589 days)
(Fig. 4).
Neither the extent of mediastinal mobilization, the
number or location of sutures, the addition of Collis gas-
troplasty, nor the mesh shape (heart, U, or C) affected risk
of recurrence.
Table 2 Operative findings
Total A B G R p
N 252 81 56 68 47
Hiatal hernia height (cm) (mean) 2.3 1.2 2.4 3.8 1.7 \0.0001
Hiatal width (cm) (mean) 2.75 2.4 2.7 3.1 3.0 \0.0001
Hiatal AP (cm) (mean) 5.3 4.8 5.4 6.1 5.3 \0.0001
Extended mediastinal mobilization [5 cm
(%)
54 % 20 % 45 % 94 % 60 % \0.0001
Collis (%) 8 % 0 % 2 % 27 % 4 % \0.0001
Toupet (%) 11 % 25 % 9 % 0 % 6 % \0.0001
No. posterior sutures (median, range) 3 (0–5) 2 (1–4) 3 (1–4) 3 (1–5) 3 (0–4)
With anterior sutures (%) 49 % 26 % 52 % 67 % 46 % \0.0001
With left sutures (%) 13 % 0 1 % 12 % 23 %
Heart-shaped Allomax (%) 24 29 23 19 22
U-shaped Allomax (%) 21 18 20 15 32
C-shaped allograft (%) 55 53 57 66 46
No. heart-shaped allografts (failures) 60 (4) 25 (1) 13 (1) 13 (1) 9 (1) ns
No. U-shaped allografts 52 (8) 14 (0) 11 (1) 11 (3) 16 (5) 0.08
No. C-shaped allografts 140 (11) 42 (2) 32 (2) 45 (2) 22 (5) 0.057
Fig. 3 Hiatal failure rates at 18-month median follow-up Fig. 4 Time to hiatal failure per group (mean, SD)
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Discussion
The most common cause of failure after primary laparo-
scopic fundoplication done for GERD is hiatal failure,
accounting for up to 90 % of failures in some series [3, 5,
14, 15]. Failure after primary suture repair of giant/para-
esophageal hiatal hernias is determined by failure of the
hiatoplasty, and rates approach 25 % at 3 years in many
studies [2, 16], though various methods of defining failure
have been used. The specific reasons for failure after
revisional surgery have infrequently been reported [17].
Since the 1980 s, operative technique for inguinal and
ventral hernia repair has undergone a paradigm shift: from
prosthetic rarely used, to prosthetic use for recurrent hernias,
to prosthetic use for large hernias, to prosthetic use even for
routine smaller hernias. The same shift to prosthetic use
cannot be said for hiatal hernia repair, and debate continues
on whether or not to use permanent or biologic prosthetics
during paraesophageal hiatal hernia repair and, to a lesser
extent, during primary laparoscopic fundoplication [11, 12].
This debate in part revolves around whether recurrence rates
are reduced, and in part around whether erosion risks
supersede any potential reduction in recurrence rates. Use of
permanent prosthetic materials in patients undergoing pri-
mary fundoplication has been demonstrated to decrease
recurrence rates compared with primary repair in random-
ized studies [18, 19]. However concerns about erosion or
permanent dysphagia have limited the adoption of perma-
nent prosthetics, not only in primary fundoplication but also
in giant/paraesophageal hiatoplasty [20]. A 2006 review of
published literature on permanent prosthetics in both pri-
mary fundoplication and paraesophageal hernia repairs
found improved outcomes in the mesh group, with very rare
instances of erosion reported. Interestingly, the authors state
that their current practice for large paraesophageal hernias
with closure under tension was to add an onlay acellular
dermal matrix [21].
In 2006, Oeschlager [13] reported that a prospective,
randomized study of porcine intestinal submucosa (Surgisis;
Cook Medical) prosthetic reinforcement of paraesophageal
hiatal hernias found a significant difference in radiographic
recurrence rates at 6 months. Five-year follow-up however
did not find a difference in radiographic or symptomatic
results [22]. Jacobs [23] in 2007 reported the outcomes of 59
(of 92) patients who underwent hiatal hernia repair without
mesh compared to 92 (of 127) patients who underwent hiatal
hernia repair with porcine intestinal submucosa reinforce-
ment. At median 3.2-year follow-up, symptomatic recur-
rence due to recurrent hiatal hernia occurred in 20 % of the
nonmesh group compared with 3.2 % of the group reinforced
with biologic graft. E. Lee [24] studied 17 patients under-
going paraesophageal hernia repair with allograft reinforce-
ment and found two radiologic recurrences at median
10-month follow-up, one of which was symptomatic. Y. Lee
[25] reported a 3.8 % radiologic and symptomatic recurrence
rate in 52 patients with allograft (AlloDerm) reinforcement
of large hiatal hernias at[1-year follow-up; however, it is not
clear that all patients had radiologic follow-up. Wisbach [26]
found 1 radiologic recurrence in 11 patients having para-
esophageal hernia repair with allograft at mean 1-year fol-
low-up. Diaz [27] found 2/46 symptomatic recurrences,
and 2/26 radiologic recurrences, in patients undergoing
paraesophageal hernia repair with allograft reinforcement
(Allomax) with 3.6-month follow-up [27]. Of note, no ero-
sions were observed in any of these studies. Persistent dys-
phagia was not reported in any of the studies other than that of
Diaz (13 %), which had a relatively short follow-up.
We began in 2007 performing routine biologic pros-
thetic reinforcement of the hiatus in all patients undergoing
surgery on the hiatus, because of our personal experience
that 90 % of primary fundoplication failures, all para-
esophageal hernia repair failures, and at least 90 % of
reoperation failures involved hiatal failure. We were not
content with these failures, even when overall failure rates
for primary fundoplication were relatively low. Concern
for erosion potential with permanent prosthetics led us to
consider biologic materials. Reports that acellular human
dermis (Alloderm) as well as porcine intestinal submucosa
prosthetic reduced recurrences in giant hiatal hernia repair
[28] were encouraging. We used one prosthetic (Allomax;
Bard, Inc.). This is a non-cross-linked allograft that rehy-
drates quickly, does not require special storage, and may
possess greater initial durability in comparison with por-
cine intestinal submucosa materials.
Our experience to date with placing this particular bio-
logic prosthetic in over 450 patients has demonstrated no
persistent dysphagia, no erosion, and minimally difficult
adhesion formation at reoperation. This is in concert with a
report from the University of Washington reporting no
erosions, strictures, or other complications related to mesh
use in 73 of 126 patients followed for a median of
45 months after laparoscopic paraesophageal hernia repair
with onlay biologic reinforcement [29].
Some patients in our series experienced early postop-
erative dysphagia severe enough to require dilation. During
dilation, the use of Maloney dilators was accompanied by
resistance that lessened with serial dilations, indicating that
hiatal fibrosis and narrowing was the likely cause. Others
have not reported problems with dysphagia, perhaps related
to different placement of the biologic patch [30]. Having
observed recurrences on the left and anterior aspect of the
hiatus, we have come to prefer a reverse-C-shaped patch
attached fairly close to the hiatal opening.
We are unaware of other studies examining differences in
hernia recurrence rates between patients undergoing primary
fundoplication, giant hiatal hernia repair, and revisional
2002 Surg Endosc (2013) 27:1997–2004
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surgery, especially utilizing a dermal allograft. This study
demonstrated a significant difference in both hiatal hernia
recurrence rates and time to recurrence between primary
fundoplication and reoperative surgery on the hiatus.
Additionally, failure rates of patients with hiatal hernias
[2 cm were similar to patients with giant hiatal hernias.
Because the current study lacks a control arm of patients
without prosthetic reinforcement, we cannot draw defini-
tive conclusions regarding whether or not the addition of a
biologic prosthetic decreases recurrence rates. It may be
that biologic grafts delay rather than prevent recurrence
[22]. Delay may be a reasonable outcome, however, as
reoperation is associated with an even higher risk of
recurrence. Safely preventing recurrence in a situation in
which the esophagus passes through a muscular opening,
with continual movement and dilation of the esophagus,
may be an unrealistic goal with current techniques. Perhaps
re-creation of a viable phrenoesophageal membrane/liga-
ment, i.e., restoration of normal anatomic constructs, will
be needed in addition to reapproximating the hiatus.
This study using biologic prosthetic in all patients
undergoing hiatal repair regardless of size found that
symptomatic recurrence rates were similar between patients
with a hiatal hernia between 2 and 5 cm (group B) and
patients with giant hiatal hernias (C6 cm axial height). This,
combined with the finding of an extremely high (23 %) hiatal
failure rate in reoperative cases despite biologic prosthetics,
suggests (but does not demonstrate) (1) that maximal therapy
be used at the first operation, (2) that whatever benefit biol-
ogics confer to giant hiatal hernia repair may extend simi-
larly to the repair of lesser hiatal hernias of [2 cm axial
height, and (3) that in reoperations, addition of biologic
prosthetics alone may not be an adequate solution.
This study is limited by (1) its retrospective nature with
incomplete follow-up (63 %, 252/400), (2) the use of clinical
criteria to define failure or success and evaluating only
clinical failures for objective evidence of hiatal hernia
recurrence, and (3) the lack of a control arm of patients not
undergoing prosthetic reinforcement. (1) With regards to
follow-up, we have found that patients with recurrent prob-
lems tend to be referred back to us and not to other centers,
and we believe that the 252 patients completing follow-up
are fairly representative of the entire group. (2) The primary
endpoint was clinical failure that was confirmed objectively
to be due to hiatal failure. Although patients had various
presenting symptoms, any recurrence of primary symptoms
or development of de novo symptoms that could indicate
recurrence was considered a clinical failure. All such clinical
failures were evaluated objectively by barium swallow or
endoscopy and determined to be objective failures if a hiatal
hernia was found. This approach is in concert with the
clinical situation that patients and practitioners face: in a
patient with recurrent symptoms, how often is that
recurrence due to hiatal failure? Other studies using radio-
graphic recurrence as a primary endpoint have demonstrated
that many radiographic recurrences are asymptomatic and do
not require reoperation [31]. (3) Although the study lacks a
control arm of patients not having a prosthetic, this study
compared outcomes among four different groups treated in
the same manner. Patients with[2 but\6 cm axial hernias
were found to have a similar rate of symptomatic recurrence
after hiatal hernia repair as did patients with giant/para-
esophageal hiatal hernias. Patients undergoing reoperative
surgery demonstrated a significantly greater hernia recur-
rence rate, and shorter time to recurrence, than patients
undergoing primary fundoplication. We believe the com-
parative findings of (a) similar recurrence rates between
patients with [2 cm axial hernias and patients with giant
hiatal hernias when an allograft was used in both groups, and
of (b) significantly worse outcomes in reoperations despite
use of a biologic prosthetic, are the most important results
of the current study.
Conclusions
This retrospective analysis of 252 patients undergoing
hiatal hernia repair reinforcement with a dermal matrix
allograft found the procedure to be safe, with a low inci-
dence of postoperative dysphagia and no issues with ero-
sion or dense adhesion formation. Additionally, at
18-month median follow-up, patients undergoing reopera-
tion had very high (23 %) recurrence rates and shorter time
to failure despite allograft use. Patients with hiatal hernias
between 2 and 5 cm axial height demonstrated failure rates
comparable to patients with giant hiatal hernias. It is
unclear whether patients with hernias of B2 cm axial
dimension benefit from prosthetic reinforcement. Patients
undergoing reoperation probably require more than allo-
graft reinforcement.
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